Back to search

Article

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders

2024-05-24

Abstract excerpt

<title>Abstract</title> <p><bold>Backgrounds: </bold>Aripiprazole(ARI) is the first-line treatment for tic disorders (TD). It is metabolized by cytochrome P450(CYP)2D6(CYP2D6) and ATP‐binding cassette, sub-family B, member 1(ABCB1) genes. However, whether the clinical efficacy/pharmacokinetics of ARI will be influenced by genetic polymorphisms is not clear. <bold>Methods: </bold>CYP2D6 and ABCB1 genotyping was pe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c8fb5b2f-0f64-5721-9e75-69cc07935689
DOI
10.21203/rs.3.rs-4408808/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disordersDOI 10.21203/rs.3.rs-4408808/v1
Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders.Semantic proximity
Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrationsSemantic proximity
Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects.Semantic proximity
Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.Semantic proximity
Population pharmacokinetics of aripiprazole in healthy Korean subjects.Semantic proximity
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.Semantic proximity
Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.Semantic proximity
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.Semantic proximity
Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.Semantic proximity
Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.Semantic proximity
Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.Semantic proximity
Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity
Select a neighboring publication to make it the new centre.